The adeno-associated virus (AAV) vector is widely used in gene function and gene therapy research due to its low immunogenicity, strong targeting ability, wide host range, non-integration into the genome, and ability to stably express exogenous genes. Compared to lentivirus (LV)-mediated or in vitro gene delivery, it is more complex to use AAV vectors in mice, which requires consideration of factors such as specific promoters, serotypes, injection methods, and observation time points. Additionally, in previous experiments, the efficiency of traditional targeted techniques for AAV capsid protein screening was low, often causing hurdles in AAV-related preclinical research projects.
Cyagen is offering a mid-year special on AAV vectors: order AAV vector packaging services by September 14, 2023 so you can enjoy a discounted price of 40% off. Experimental development of the packaged AAV vectors will be completed in as fast as 3 weeks, and a standard control vector will be provided for free! We can provide a full range of AAV services as part of our professional gene therapy CRO service platform, including artificial intelligence (AI)-guided screening of AAV capsids, AAV vector construction and development, in vivo injections, downstream efficacy evaluation, and more. We can deliver everything for your AAV project to achieve high productivity and tissue delivery in an accelerated timeline compared to traditional methods. Our AI-guided AAV screening has achieved multiple breakthroughs for preclinical research, including: achieving limitless library capacity, replacing the need for wet lab experiments to generate new sequences, and shortening the screening cycle of an optimal mutant from at least 3 years (in traditional directed evolution) to approximately 1 year. Additionally, conserving the environment of animal models helps reduce stress-related biological impacts caused by the shipment process and ensures the consistency of your project's research data. Contact us at 800-921-8930 or
email firstname.lastname@example.org for more information.
AI-Guided Rapid Screening of AAV
AAV Vector High-Titer Packaging
Efficacy Evaluation System (e.g. AAV Vector Injection)
AAV capsid proteins play a crucial role in gene therapy and vaccine development. However,
traditional directed evolution screening techniques have limitations such as limited library
capacity, low success rate, and low screening efficiency. To address this issue, Cyagen has
developed a predictive AI model using deep learning to efficiently screen AAV mutants for
multi-target gene therapy drugs. This model enables us to achieve targeted predictions for various
sites, such as brain targeting, full ocular expression capability, and ocular penetration.
Compared to traditional directed evolution, AI-assisted screening of AAV has achieved
multidimensional breakthroughs, including:
Limitless library capacity
Taking the traditional AAV9 561-588 amino acid region mutant library as an
example, the maximum capacity of the DNA library is 109, while the sequence
capacity achieved through AI deep learning screening can reach 1050.
Using AI models instead of wet lab experiments to generate new sequences
AI is used to screen parameters such as high yield and tissue targeting,
and then the data is synthesized through the AI model algorithms to suggest capsid
designs anticipated to have high productivity and tissue delivery. This effectively
avoids the limitations of library synthesis capacity in traditional wet lab experiments.
Shortened screening cycle from at least 3 years to approximately 1 year,
leading to a 3-6 times increase in efficiency
To obtain the optimal mutant in traditional directed evolution, it often
requires 3-6 rounds of experiments from library synthesis to screening. By utilizing AI
technology, enough data can be obtained through 1-2 rounds of screening.
Brain targeting prediction
Figure 1. Brain targeting prediction
Figure 2. Perform intravenous tail injection with 3E11 vg (viral
genomes) per mouse and evaluate after 3 weeks.
Prediction of overall ocular expression capability
Figure 3. Prediction of AAV overall ocular expression efficiency
Figure 4. Intravitreal injection of 1E10 vg/eye and detection of
overall ocular anti-VEGF protein levels after 27 days.
Prediction of ocular penetration ability
Figure 5. Prediction of AAV ocular penetration efficiency.
Figure 6. Intravitreal injection of 3E9 vg/eye and fluorescence
imaging of the fundus at 18 days, followed by histological analysis of retinal
sections at 21 days to assess viral expression efficiency.
Cyagen offers a range of services from AAV vector design and construction to virus packaging,
purification, expression analysis, and functional validation. These services aim to minimize the
experimental timeline for clients. Various titer specifications are available, and stringent
purification processes are employed to ensure efficient expression of exogenous human/mouse ORFs,
shRNA, lncRNA, and CRISPR/gRNA.
Promotion Period: July 14th to September
Event Details: Enjoy a 40% discount on the following virus
packaging services, with fast delivery within 3 weeks, plus a complimentary standard control
AAV1、8、9 and php.eb
1.The cost of cDNA synthesis and vector construction are not included.
2.Control AAV will be provided for free, with titers ranging from 20% to 33% of the experimental
3.The pricing above is based on the premise that it does not exceed the AAV viral packaging range.
If it exceeds the packaging range, consultation is required. The maximum sequence length that can be
accommodated between ITRs is 4.5 kb (including ITR length).
4.The promotion is applicable only to standalone AAV packaging projects and does not apply to AAV
packaging quotes within gene therapy comprehensive projects.
* Bonus note
We also provide virus packaging services for lentivirus (LV), adenovirus (AdV), and higher-titer
specifications for AAV virus packaging services upon request. Contact us for more info!
AAV infection of cells in vitro
We infected 293T cells with AAV2, AAV8, and AAV9 at MOI (multiplicity of infection)
values of 1E5, 1E4, 1E3, and 1E2, respectively. After 48 hours, we observed significant
fluorescence intensity. Among them, AAV2 (MOI=1E5) achieved a GFP positive rate of
Obtaining the virus through packaging is just the beginning, as there are still important steps such
as injection into animal bodies and subsequent efficacy evaluations, which have a significant impact
on the success of the project. Cyagen can provide a variety of AAV vector injection services for
mice, including common routes such as tail vein, intraperitoneal, ocular, brain, and intramuscular
injections. We can also help you access downstream drug efficacy service platforms, enabling you to
obtain accurate research conclusions through physiological and biochemical analysis, pathology
analysis, metabolism analysis, gene and protein expression analysis, and cell function testing to
better utilize phenotype verification.
Intravitreal injection (into the subretinal/vitreous cavity of the eye)
Stereotactic injection into the hippocampus/lateral ventricle of the brain
Intratracheal (pulmonary) injection
Intrathecal injection (into the brain/spinal cord)
Short Project Cycle
Utilizing AI deep learning technology to assist in screening AAV capsid proteins reduces the cost of
experimental trial and error and overall screening time. Multiple tissue-specific promoter stock
vectors are available for selection on a mature technology platform and customized virus packaging
can be as fast as 3 weeks. With multistep safeguards, researchers are able to significantly shorten
the experimental cycle.
Stable Validation Data
The viruses are validated for infection efficacy by our internal technical team through in vitro cell and in vivo mouse models, ensuring quality control. Additionally, we have the backing of literature citations and project performance from external research clients, providing a dual guarantee that allows you to confidently use AAV vectors that meet your requirements.
Various Types of Viruses to Choose from
We offer customized packaging services for various serotypes of AAVs, as well as lentivirus and adenovirus vectors. You have the freedom to choose from different gradient specifications, and we can achieve gene overexpression, knockdown (shRNA), and gene editing capabilities.
Comprehensive Service Platform
Cyagen provides a CRO service platform that offers support from AI-assisted efficient screening of AAV mutants to virus vector construction and development, as well as downstream efficacy evaluation. Conserving the environment of animal models helps reduce stress-related biological impacts caused by the shipment process and ensures the consistency of project research data.